SINGULAR HEALTH GROUP LTD — Director's Dealing 2022

Dec 28, 2022

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Singular Health Group Limited
ABN	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Denning Chong
Date of last notice	15 February 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect Securities held by JCC Health Pty Ltd MEDVR A/C>, entity controlled by Mr Chong and of which he is a beneficiary
Date of change	21 December 2022
No. of securities held prior to change	Indirect (i) 4,380,000 fully paid ordinary shares – escrowed to 12 February 2023 (ii) 1,200,000 Class A Performance Rights – escrowed to 12 February 2023 (iii) 1,200,000 Class B Performance Rights – escrowed to 12 February 2023 (iv) 4,500,000 Unlisted Options ($0.30, 10 February 2025), escrowed to 12 February 2023
Class	Fully paid ordinary shares Performance Rights, Subject to vesting, expiring 23 December 2025
Number acquired	i) 260,869 shares ii) 1,500,000 performance rights
Number disposed	Nil

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$30,000 paid for shares. Performance rights issued as per the rationale set out in the 2022 AGM Notice of Meeting. Valuation as set out in the NOM is $131,658.
No. of securities held after change	Direct (i) 4,640,869 fully paid ordinary shares (4,380,000 escrowed to 12 Feb 2023) (ii) 1,200,000 Class A Performance Rights – escrowed to 12 February 2023 (iii) 1,200,000 Class B Performance Rights – escrowed to 12 February 2023 (iv) 4,500,000 Unlisted Options ($0.30, 10 February 2025), escrowed to 12 February 2023 (v) 1,500,000 Performance Rights, Subject to vesting, expiring 23 December 2025
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Shares – acquired via participation in Share Purchase Plan. Performance Rights – as approved by shareholders at the 2022 AGM held 28 November 2022.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above No traded during a[+] closed period where prior written clearance was required?

If so, was prior written clearance provided to allow the trade to n/a proceed during this period?

If prior written clearance was provided, on what date was this n/a provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Singular Health Group Limited
ABN	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Howard Digby
Date of last notice	15 February 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect LAMMA NOMINEES PTY LTD MIDDLETON A/C>, entity controlled by Mr Digby, and of which he is a beneficiary
Date of change	21 December 2022
No. of securities held prior to change	Direct (i) 50,000 fully paid ordinary shares (ii) 1,000,000 Unlisted options ($0.30, 10 February 2025), escrowed to 12 February 2023 Indirect i) 35,000 Fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	Direct i) 217,391 shares Indirect i) Nil
Number disposed	Nil

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$25,000
No. of securities held after change	Direct (i) 267,391 fully paid ordinary shares (ii) 1,000,000 Unlisted Options ($0.30, 10 February 2025), escrowed to 12 February 2023 Indirect (i) 35,000 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Shares acquired via participation in Share Purchase Plan.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Singular Health Group Limited
ABN	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Thomas Hanly
Date of last notice	13 December 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect Securities held by Sylvan Capital Pte Ltd – an entity controlled by Mr Hanly, and of which he is a beneficiary.
Date of change	21 December 2022, 23 December 2022
No. of securities held prior to change	Direct (i) 1 fully paid ordinary share – escrowed to 12 February 2023 (ii) 1,500,000 Class A Performance Rights – escrowed to 12 February 2023 (iii) 1,500,000 Class B Performance Rights – escrowed to 12 February 2023 (iv) 6,000,000 Unlisted Options ($0.30, 10 February 2025), escrowed to 12 February 2023 (v) 35,990 fully paid ordinary shares Indirect i) 100,000 fully paid ordinary shares ii) 3,400,000 fully paid ordinary shares – escrowed to 12 February 2023

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Fully paid ordinary shares Performance Rights, Subject to vesting, expiring 23 December 2025
Number acquired	Direct i) 86,956 shares ii) 1,500,000 performance rights Indirect i) Nil
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$10,000 paid for shares. Performance rights issued as per the rationale set out in the 2022 AGM Notice of Meeting. Valuation as set out in the NOM is $131,658.
No. of securities held after change	Direct (i) 1 fully paid ordinary share – escrowed to 12 February 2023 (ii) 1,500,000 Class A Performance Rights – escrowed to 12 February 2023 (iii) 1,500,000 Class B Performance Rights – escrowed to 12 February 2023 (iv) 6,000,000 Unlisted Options ($0.30, 10 February 2025), escrowed to 12 February 2023 (v) 122,946 fully paid ordinary shares (vi) 1,500,000 Performance Rights, Subject to vesting, expiring 23 December 2025 Indirect (i) 100,000 fully paid ordinary shares (ii) 3,400,000 fully paid ordinary shares – escrowed to 12 February 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Shares – acquired via participation in Share Purchase Plan. Performance Rights – as approved by shareholders at the 2022 AGM held 28 November 2022.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Detail of contract	n/a
	Nature of interest	n/a
	Name of registered holder (if issued securities)	n/a
	Date of change	n/a

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3